The medical community is excited with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 target that’s demonstrating significant potential in clinical trials for managing obesity. Unlike some current weight loss approaches, retatrutide appears to deliver a greater substantial reduction in body size and improve metabolic markers